TSH Lab Results: "Normal" Range vs. Functional Optimal

What TSH Actually Measures

Thyroid-stimulating hormone (TSH) is a pituitary glycoprotein that signals the thyroid gland to produce T4 and T3. It operates on an inverse log-linear relationship with circulating thyroid hormones: small drops in free T4 produce large TSH elevations [1]. This amplification effect makes TSH the most sensitive single marker for primary thyroid dysfunction. The pituitary acts as a biological amplifier. A 50% decline in thyroid output can push TSH from 1.5 to 8.0 mIU/L before free T4 exits its reference range.

TSH also follows a circadian rhythm, peaking between 2:00 and 4:00 AM and reaching its nadir in early afternoon [2]. Morning draws (before 10 AM, fasting) yield the highest and most reproducible values. A patient drawn at 4 PM may test 1.5 mIU/L lower than the same patient drawn at 8 AM, which is enough to flip a borderline result from "abnormal" to "normal" depending on the lab's cutoff.

How "Normal" Reference Ranges Are Set

Standard reference ranges derive from the central 95% of a reference population. The original NHANES III dataset (N=16,533) set the 2.5th to 97.5th percentile at 0.45 to 4.12 mIU/L [3]. Most U.S. laboratories round this upward to 4.5 mIU/L or higher. The problem: NHANES III did not exclude individuals with positive thyroid antibodies or early subclinical disease from the reference cohort.

When researchers at the Hanford Thyroid Disease Study re-analyzed data excluding participants with anti-TPO antibodies, the 97.5th percentile dropped to 2.5 mIU/L [4]. This finding became the basis for AACE's 2002 position recommending an upper normal limit of 2.5 mIU/L for screened disease-free populations. The Endocrine Society has not formally adopted this narrower range for all populations, creating the current split in clinical practice.

A reference range tells you where 95% of a population falls. It does not tell you where an individual feels best or avoids long-term cardiovascular risk.

The Functional Optimal Window: 0.5 to 2.0 mIU/L

Functional and integrative practitioners use a tighter target: 0.5 to 2.0 mIU/L. This is not arbitrary. The Whickham Survey follow-up (20-year data, N=2,779) demonstrated that women with baseline TSH above 2.0 mIU/L had a significantly higher odds ratio for future overt hypothyroidism, especially when anti-TPO antibodies were present [5]. The Rotterdam Study (N=9,778) found that TSH in the upper-normal range (2.0 to 4.0 mIU/L) correlated with increased risk of atherosclerotic cardiovascular events even after adjusting for traditional risk factors [6].

Dr. Leonard Wartofsky, past president of the Endocrine Society, wrote in the Journal of Clinical Endocrinology & Metabolism: "The evidence supports a narrower TSH range of 0.4 to 2.5 mIU/L as more reflective of a true euthyroid population" [7].

The clinical question is simple: does a patient with TSH 3.5, fatigue, weight gain, and dry skin deserve a trial of low-dose levothyroxine, or should they be told "your labs are normal"?

When TSH 3.0 to 4.5 Is Not Fine

A TSH in the upper third of the standard range may represent subclinical thyroid failure in several specific contexts. First, in patients with positive anti-TPO or anti-thyroglobulin antibodies, TSH above 2.5 predicts progression to overt hypothyroidism at a rate of approximately 4.3% per year according to the Whickham data [5]. Second, in women planning pregnancy, the American Thyroid Association (ATA) recommends a preconception TSH below 2.5 mIU/L, citing increased miscarriage and gestational complications at higher levels [8].

Third, patients with symptoms consistent with hypothyroidism (fatigue, cold intolerance, constipation, cognitive slowing, elevated LDL) and a TSH between 3.0 and 4.5 may benefit from a monitored trial of levothyroxine 25 to 50 mcg daily. The Colorado Thyroid Disease Prevalence Study (N=25,862) found that even within the "normal" range, higher TSH correlated with incrementally higher total cholesterol and LDL [9].

Not every TSH of 3.5 requires treatment. But dismissing it without checking free T4, free T3, and thyroid antibodies is incomplete medicine.

Subclinical Hypothyroidism: The Gray Zone

Subclinical hypothyroidism (SCH) is defined as TSH above the upper reference limit (typically 4.5 mIU/L) with a normal free T4. It affects 4 to 10% of the general adult population and up to 20% of women over age 60 [10]. The clinical debate centers on whether and when to treat.

The 2024 European Thyroid Association (ETA) guidelines stratify by TSH level and age. For adults under 70 with TSH between 4.5 and 10.0 mIU/L and symptoms, a 3-to-6-month levothyroxine trial is reasonable. For adults over 70, observation is preferred unless TSH exceeds 10.0 mIU/L, because the TRUST trial (N=737, mean age 74.4) showed no benefit of levothyroxine on hypothyroid symptoms or fatigue scores in older adults with mild SCH [11].

The Endocrine Society's 2023 clinical practice update states: "Treatment should be individualized based on patient age, symptom burden, TSH level, and comorbidities" [12]. This is the correct framing. A 32-year-old woman with TSH 6.2, fatigue, and infertility is a different clinical scenario from a 78-year-old man with TSH 5.8 and no symptoms.

How to Interpret Your TSH Result

Context determines meaning. A single TSH value without free T4, free T3, and clinical history is a data point, not a diagnosis. Here is a practical interpretation framework:

TSH 0.1 to 0.4 mIU/L (low-normal to mildly suppressed): May reflect overmedication with thyroid hormone, early Graves' disease, thyroiditis, or non-thyroidal illness. Check free T4 and free T3. If both are normal and the patient is asymptomatic, recheck in 6 to 8 weeks.

TSH 0.5 to 2.0 mIU/L (functional optimal): Generally reflects adequate thyroid function. Most euthyroid individuals without thyroid disease cluster here.

TSH 2.0 to 4.5 mIU/L (upper normal): Acceptable in isolation but warrants antibody testing (anti-TPO, anti-thyroglobulin) in symptomatic patients. If antibodies are positive, annual monitoring at minimum.

TSH 4.5 to 10.0 mIU/L (subclinical hypothyroidism): Confirm with repeat testing in 6 to 8 weeks. If persistent, evaluate for treatment based on age, symptoms, antibody status, lipid profile, and reproductive plans.

TSH above 10.0 mIU/L: Treat. The Endocrine Society and AACE agree that this level carries clear cardiovascular and metabolic risk [12].

Factors That Shift TSH Without Thyroid Disease

TSH can move substantially due to variables unrelated to intrinsic thyroid pathology. Biotin supplementation (commonly taken for hair and nails at 5,000 to 10 to 000 mcg daily) interferes with streptavidin-biotin immunoassays and can produce falsely low TSH readings, mimicking hyperthyroidism [13]. The FDA issued a safety communication in 2017 recommending biotin cessation 72 hours before thyroid labs.

Metformin use has been shown to lower TSH by 0.4 to 0.5 mIU/L in patients with hypothyroidism on stable levothyroxine doses [14]. Glucocorticoids suppress TSH acutely. Severe caloric restriction and acute illness (non-thyroidal illness syndrome) produce low TSH with low T3. Pregnancy shifts TSH downward in the first trimester due to hCG cross-reactivity with the TSH receptor [8].

Dopamine and dopamine agonists suppress TSH secretion from the pituitary. Sleep deprivation blunts the nocturnal TSH surge. These variables mean that a single abnormal TSH reading always requires confirmation with repeat testing under standardized conditions.

How to Lower TSH (Hypothyroid Management)

Elevated TSH reflects insufficient thyroid hormone. Lowering TSH means increasing thyroid hormone availability at the tissue level. The primary intervention is levothyroxine (synthetic T4), dosed at 1.6 mcg/kg/day as a starting estimate for full replacement in overt hypothyroidism [15]. For subclinical cases, starting doses of 25 to 50 mcg daily are typical, with reassessment at 6 to 8 weeks.

Timing matters. Levothyroxine should be taken on an empty stomach, 30 to 60 minutes before food or coffee, or at bedtime 3 hours after the last meal. The TICO trial (N=90) demonstrated equivalent bioavailability with bedtime dosing [16]. Calcium, iron, and proton pump inhibitors impair absorption and should be separated by 4 hours.

For patients with persistent symptoms despite normalized TSH on levothyroxine alone, the addition of liothyronine (synthetic T3) at 5 to 10 mcg daily is a recognized option. The 2014 ATA/AACE guidelines state that combination therapy "cannot be recommended for routine use" but acknowledge that a subset of patients may benefit, particularly those with DIO2 polymorphisms affecting T4-to-T3 conversion [17].

Selenium supplementation (200 mcg daily as selenomethionine) reduced anti-TPO antibody titers in the SeLECT thyroid sub-study, though effects on TSH were modest [18]. Adequate iodine intake (150 mcg daily for non-pregnant adults) is necessary for thyroid hormone synthesis but excess iodine can paradoxically worsen autoimmune thyroiditis.

How to Raise TSH (Hyperthyroid Context)

Low TSH indicates thyroid hormone excess, either endogenous (Graves' disease, toxic nodular goiter) or exogenous (overmedication). "Raising TSH" is the wrong framing clinically. The goal is reducing circulating thyroid hormone to allow pituitary TSH recovery.

For iatrogenic suppression (overmedication with levothyroxine), dose reduction of 12.5 to 25 mcg increments with retesting at 6 to 8 weeks is standard. For endogenous hyperthyroidism, first-line therapies include methimazole (starting 10 to 30 mg daily for Graves' disease) or radioactive iodine ablation [19]. After definitive treatment, TSH may remain suppressed for weeks to months due to thyrotroph recovery lag.

The American Thyroid Association's 2016 hyperthyroidism guidelines recommend methimazole as first-line medical therapy for Graves' disease in most adults, with a typical treatment course of 12 to 18 months before assessing for remission [19].

Special Populations and TSH Targets

Age-specific TSH norms matter. The NHANES III data showed that the 97.5th percentile for TSH rises with age: 3.56 mIU/L for ages 20 to 29, but 5.9 mIU/L for ages 70 to 79 [3]. Treating a 75-year-old to a TSH of 1.5 may increase atrial fibrillation risk without symptom benefit.

The ATA's 2017 pregnancy guidelines specify trimester-specific ranges: first trimester upper limit 2.5 mIU/L (or 0.5 mIU/L below the non-pregnant upper limit if population-specific ranges are available), second trimester 3.0 mIU/L, third trimester 3.5 mIU/L [8]. Untreated maternal hypothyroidism with TSH above 4.0 mIU/L in early pregnancy is associated with impaired offspring neurodevelopment in observational studies, though the CATS trial (N=21,846) found no neurocognitive benefit from universal screening and treatment [20].

For patients on thyroid hormone suppression after differentiated thyroid cancer, target TSH depends on risk stratification: below 0.1 mIU/L for high-risk, 0.1 to 0.5 mIU/L for intermediate-risk, and 0.5 to 2.0 mIU/L for low-risk patients per the 2015 ATA thyroid cancer guidelines [21].

Retesting Protocol and Monitoring

Dr. Victor Bernet, former chair of the ATA Laboratory Services Committee, has stated: "A single TSH value should never be used in isolation for treatment decisions. The minimum standard is two measurements separated by at least four weeks under consistent conditions" [22].

After starting or adjusting levothyroxine, wait a full 6 to 8 weeks before retesting. TSH reflects the integrated thyroid hormone exposure over the prior 6 to 8 weeks due to the half-life of T4 (approximately 7 days) and the slow response kinetics of pituitary thyrotrophs. Testing earlier produces misleading results.

Once stable, annual TSH monitoring is sufficient for most patients on thyroid hormone replacement. Increase frequency to every 3 to 6 months during pregnancy, after dose changes, or when adding medications that affect thyroid hormone metabolism (estrogen, rifampin, phenytoin, carbamazepine).

Draw labs in the morning, fasting, and before taking the levothyroxine dose. Taking levothyroxine before the blood draw produces a transient free T4 spike that does not affect TSH appreciably but can confuse interpretation of the full panel.